

Norway-Oslo: Influenza vaccines

OJ S 222/2021 16/11/2021

Contract notice

Supplies

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority

I.1. Name and addresses

Official name: Folkehelseinstituttet

National registration number: 983 744 516

Postal address: Postboks 222 Skøyen

Town: OSLO

NUTS code: NO Norge

Postal code: 0213

Country: Norway

Contact person: Ole Andreas Fuglesang

E-mail: ole.andreas.fuglesang@fhi.no

Telephone: +47 21076629

Internet address(es):

Main address: <http://www.fhi.no>

Address of the buyer profile: <https://eu.eu-supply.com/ctm/Company/CompanyInformation/Index/346372>

I.3. Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at: http://eu.eu-supply.com/app/rfq/rwlenrance_s.asp?PID=315779&B=DFO

Additional information can be obtained from the abovementioned address

Tenders or requests to participate must be submitted electronically via: http://eu.eu-supply.com/app/rfq/rwlenrance_s.asp?PID=315779&B=DFO

Tenders or requests to participate must be submitted to the abovementioned address

I.4. Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

I.5. Main activity

Health

Section II: Object

II.1. Scope of the procurement

II.1.1. Title

Four valent vaccine against seasonal influenza - Supplementary volume for the season 2022 /2023

Reference number: 21/16624

II.1.2.

Main CPV code

33651660 Influenza vaccines

II.1.3. Type of contract

Supplies

II.1.4. Short description

Folkehelseinstituttet [the Norwegian Institute of Public Health] is holding an open tender contest with the aim of ensuring sufficient delivery of four valent vaccine against seasonal influenza (ATC code J07B B02) for vaccination of adults in defined risk groups for the seasons 2022/2023.

II.1.5. Estimated total value

Value excluding VAT: 98 000 000,00 NOK

II.1.6. Information about lots

This contract is divided into lots: yes
Tenders may be submitted for all lots

II.2. Description**II.2.1. Title**

Four valent vaccine against seasonal influenza - Supplementary volume for the season 2022 /2023
Lot No: 1

II.2.2. Additional CPV code(s)

33651660 Influenza vaccines

II.2.3. Place of performance

NUTS code: NO Norge
Main site or place of performance: Oslo

II.2.4. Description of the procurement

Folkehelseinstituttet [the Norwegian Institute of Public Health] is holding an open tender contest with the aim of ensuring sufficient delivery of four valent vaccine against seasonal influenza (ATC code J07B B02) for vaccination of adults in defined risk groups (see point 1.4) for the seasons 2022/2023.

The Norwegian Institute of Public Health already has the existing contracts for four valent seasonal influenza vaccine for the season 2022/2023 with respectively Sanofi Aventis (Vaxigriptetra) and Mylan Healthcare (Influvac Tetra), with a combined volume of 900,000 doses. Increased national request for seasonal influenza vaccine in recent years makes it necessary to carry out supplementary procurement for the season 2022/2023, in order to cover the need beyond the volume in the existing contracts.

The only award criteria in the competition is lowest price. The tender documentation has several minimum requirements for the vaccine. All the minimum requirements must be fulfilled. The procurement will be carried out in accordance with the Public Procurement Act of 17 June 2016 (PPA) and the Public Procurement Regulations (PPR) part I and part III. A contract will be awarded in accordance with the open tender contest procedure, cf. the Public Procurement Regulations § 13-1 (1).

FHI has received signal that there will be significant risk that doses cannot be allocated to Norway if the procurement process is not carried out before the middle of December. As FHI cannot risk Norway being left without doses, it has been decided to hold a contest with a 15

day tender deadline. Incidentally, the procurement will be carried out in-line with the procurement regulations.

The total contract volume is 700,000 - 900,000 doses

In this contest, the Norwegian Institute of Public Health in consideration of preparedness, will primarily aims to award two sub-contracts where the total volume is distributed as follows:

60% of total volume, 420,000 - 540,000 doses

40% of total volume, 280,000 - 360,000 doses

The actual number of doses will be clear upon award.

See Chapter 6 of the tender documentation 'Award Criteria' with sub-points for further description.

Also see the tender documentation point 1.9 'Special contract terms'

First delivery in the new contract is anticipated to be before 20 September 2022.

Contract terms are given in Annex 1, 'Supply Agreement'.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

Value excluding VAT: 98 000 000,00 NOK

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 10/12/2021

This contract is subject to renewal: no

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

II.2. Description

II.2.1. Title

Four valent vaccine against seasonal influenza - Supplementary volume for the season 2022 /2023

Lot No: 2

II.2.2. Additional CPV code(s)

33651660 Influenza vaccines

II.2.3. Place of performance

NUTS code: NO Norge

Main site or place of performance: Oslo

II.2.4. Description of the procurement

Folkehelseinstituttet [the Norwegian Institute of Public Health] is holding an open tender contest with the aim of ensuring sufficient delivery of four valent vaccine against seasonal

influenza (ATC code J07B B02) for vaccination of adults in defined risk groups (see point 1.4) for the seasons 2022/2023.

The Norwegian Institute of Public Health already has the existing contracts for four valent seasonal influenza vaccine for the season 2022/2023 with respectively Sanofi Aventis (Vaxigriptetra) and Mylan Healthcare (Influvac Tetra), with a combined volume of 900,000 doses. Increased national request for seasonal influenza vaccine in recent years makes it necessary to carry out supplementary procurement for the season 2022/2023, in order to cover the need beyond the volume in the existing contracts.

The only award criteria in the competition is lowest price. The tender documentation has several minimum requirements for the vaccine. All the minimum requirements must be fulfilled. The procurement will be carried out in accordance with the Public Procurement Act of 17 June 2016 (PPA) and the Public Procurement Regulations (PPR) part I and part III. A contract will be awarded in accordance with the open tender contest procedure, cf. the Public Procurement Regulations § 13-1 (1).

FHI has received signal that there will be significant risk that doses cannot be allocated to Norway if the procurement process is not carried out before the middle of December. As FHI cannot risk Norway being left without doses, it has been decided to hold a contest with a 15 day tender deadline. Incidentally, the procurement will be carried out in-line with the procurement regulations.

The total contract volume is 700,000 - 900,000 doses

In this contest, the Norwegian Institute of Public Health in consideration of preparedness, will primarily aims to award two sub-contracts where the total volume is distributed as follows:

60% of total volume, 420,000 - 540,000 doses

40% of total volume, 280,000 - 360,000 doses

The actual number of doses will be clear upon award.

See Chapter 6 of the tender documentation 'Award Criteria' with sub-points for further description.

Also see the tender documentation point 1.9 'Special contract terms'

First delivery in the new contract is anticipated to be before 20 September 2022.

Contract terms are given in Annex 1, 'Supply Agreement'.

II.2.5. Award criteria

Criteria below

Price

II.2.6. Estimated value

II.2.7. Duration of the contract, framework agreement or dynamic purchasing system

Start: 10/12/2021

This contract is subject to renewal: no

II.2.10. Information about variants

Variants will be accepted: no

II.2.11. Information about options

Options: no

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

Section III: Legal, economic, financial and technical information

III.1. Conditions for participation

III.1.1. Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers

List and brief description of conditions:

Tenderers must be registered in a company register, professional register or a trade register in the country where the tenderer is established.

Documentation requirement:

Norwegian companies: Company registration certificate

Foreign tenderers: Verification showing that the tenderer is registered in a company register, professional register or a commerce register in the country where the tenderer is established.

III.1.3. Technical and professional ability

List and brief description of selection criteria:

The tenderer must have the requisite permissions to be able to fulfil the contract.

Documentation requirement:

If the tenderer is the manufacturer of the vaccine, permission must be presented from relevant EU/EEA authorities to manufacture pharmaceuticals.

If the tenderer is not the manufacturer of the vaccine, the requisite permissions from relevant EU/EEA authorities to trade in pharmaceuticals must be presented.

If the tenderer imports the vaccine, the import license that includes the offered vaccine must be presented.

NB: for instances where tenderers are a Norwegian company it is sufficient to present a Norwegian manufacturer's or wholesaler's license that applies to the Norwegian company.

III.2. Conditions related to the contract

III.2.2. Contract performance conditions

- Supplier no. 1 is obligated for the 2022/2023 season to be able to deliver at a minimum the awarded number of doses in accordance with the agreed delivery plan (Supply Agreement point 3.2, bullet point 1)
 - Supplier no. 2 is obligated for the 2022/2023 season to be able to deliver at a minimum the awarded number of doses in accordance with the agreed delivery plan (Supply Agreement point 3.2, bullet point 2)
 - Supply Agreement point 4.2 states requirements for delivery volume within given deadlines. If the received tenders indicate a different distribution (than 60-40%), refer to the tender documentation point 6.1, the indication of supplier and volume in the Supply Agreement point 1.3, 3.2, 3.3, 4.2 and 6.2, can be changed to suit the given situation.
- Also see the tender documentation point 1.9

Section IV: Procedure

IV.1. Description

IV.1.1. Type of procedure

Open procedure

IV.1.3. Information about a framework agreement or a dynamic purchasing system

IV.1.8.

Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: yes

IV.2. Administrative information

IV.2.2. Time limit for receipt of tenders or requests to participate

Date: 26/11/2021 Local time: 13:00

IV.2.3. Estimated date of dispatch of invitations to tender or to participate to selected candidates

IV.2.4. Languages in which tenders or requests to participate may be submitted

Norwegian

IV.2.6. Minimum time frame during which the tenderer must maintain the tender

Tender must be valid until: 31/12/2021

IV.2.7. Conditions for opening of tenders

Date: 26/11/2021 Local time: 13:00

Place:

Electronic opening in the Norwegian Institute of Public Health's tender implementation tool system.

Information about authorised persons and opening procedure: Tender opening requires two of the Norwegian Institute of Public Health's employees with defined user-access in the system log in and implement opening.

Section VI: Complementary information

VI.1. Information about recurrence

This is a recurrent procurement: no

VI.3. Additional information

VI.4. Procedures for review

VI.4.1. Review body

Official name: Oslo tingrett

Postal address: Postboks 2106 Vika

Town: Oslo

Postal code: 0125

Country: Norway

E-mail: oslo.tingrett@domstol.no

Telephone: +47 22035200

VI.5. Date of dispatch of this notice

11/11/2021